Next Article in Journal
Design of Nickel Supported Hierarchical ZSM-5/USY Zeolite Bifunctional Catalysts for One-Pot Menthol Synthesis via Liquid-Phase Citral Hydrogenation
Next Article in Special Issue
Hepatoprotective Effect of Curcumin Nano-Lipid Carrier against Cypermethrin Toxicity by Countering the Oxidative, Inflammatory, and Apoptotic Changes in Wistar Rats
Previous Article in Journal
Amino Derivatives of Diaryl Pyrimidines and Azolopyrimidines as Protective Agents against LPS-Induced Acute Lung Injury
Previous Article in Special Issue
Investigating the Mechanisms of Bisdemethoxycurcumin in Ulcerative Colitis: Network Pharmacology and Experimental Verification
 
 
Review
Peer-Review Record

The Effects of Curcumin on Inflammasome: Latest Update

Molecules 2023, 28(2), 742; https://doi.org/10.3390/molecules28020742
by Tarek Benameur 1,†, Socorro Vanesca Frota Gaban 2,†, Giulia Giacomucci 3, Francesca Martina Filannino 4, Teresa Trotta 4, Rita Polito 4, Giovanni Messina 4, Chiara Porro 4,* and Maria Antonietta Panaro 5
Reviewer 1:
Reviewer 2:
Molecules 2023, 28(2), 742; https://doi.org/10.3390/molecules28020742
Submission received: 15 December 2022 / Revised: 3 January 2023 / Accepted: 9 January 2023 / Published: 11 January 2023

Round 1

Reviewer 1 Report

The topic of the research article is of great interest. However, I would not recommend publishing the article in its current format as it requires lots of improvement. The main drawbacks of this manuscript

 Below are several specific comments.
1. The English writing should be further improved, as there are many grammatical or typing errors.

2. The whole manuscript is mixed between American English and British English. The authors even use British English or American English. For consistency, consider replacing it with the American English spelling.

3. Some references not according to journal instructions

4. Reference no. 86 should be 2021 not 2012

5-The authors used around 115 references as it's well-known that a review paper should use the last 5 years of literature, to obtain the most relevant information. The percentages of the last 5 years of references were 53.9 % (62 references) while old references were. 46.1 % (53 references).

6. Some types, grammar, and style errors need to be corrected listed below

line 18 changes protein to proteins

line 23 adds a comma before and

line 25 adds a comma after review

line 40 removes the comma after longa                                                                

line 48 adds the or an before excessive

line 55 adds a comma before and

line 58 changes for to of

line 72 changes resultings to resulting

line 93 adds a comma after hsp90

line 99 removes the comma after Caspase-1

line 100 adds a comma before and

line 102 changes are to is

line 109 changes activate to activates

line 111 changes (IALRs) to (ALRs)

line 114 adds and before AIM2    

line 114 changes carboxyl terminal to carboxyl-terminal 

line 115 changes recognizes to recognize

line 116 changes NATCHT to NACHT

line 126 adds are before known

line 126 changes activates to activate

line 135 adds a before cellular

line 144 changes tumour to tumor

line 156 changes defence to defense

line 156 changes Bacillus anthraces to Bacillus anthracis

line 158 changes toxin to toxins       

line 161 changes best characterized to best-characterized

Line 170 changes are to is    

Line 172 adds the before cytosolic  

Line 173 adds are before somehow

Line 177 adds the ore an before  optimal  

line 180 changes signalling to signaling

Line 189 adds the before PYD

Line 189 changes pro-caspsase-1 to pro-caspase-1

line 209 changes import to important

line 211 changes in to on

lines 212 and 216 removes the comma before activated

line 222 changes channel, resulting in an increase in to channels, increasing

line 228 adds the before brain

line 256 removes of

line 264 adds a comma after specifically

line 266 changes nanotheranostic to nano theranostics

line 276 removes the comma after NLRP3

line 277 adds the before NLRP3

line 278 changes speck like to speck-like

line 288 adds been before fully

line 294 removes of

line 298 adds a comma before and

line 303 changes on to for

line 304 changes property to properties

line 333 removes the before acute     

line 342 changes signalling to signaling

line 365 changes that that to that

line 374 changes modulate to modulates

line 375 changes regulate to regulates

line 390 changes signalling to signaling

line 393 removes the after support

line 400 changes agent’s to agents

line 414 adds an before important

Line 418 adds an before inflammatory

Line 418 changes tissues to tissue

Line 421 changes mice to mice’s

Line 423 adds a comma before and   

Line 426 removes as

Line 427 removes a before severe

Line 436 adds are before listed

Line 439 remove an

line 442 adds a comma before and

lines 448 and 449 change signalling to signaling

line 462 changes to unravel to unraveling

line 464 changes nanocurcumin to nano curcumin

line 468 removes the comma before were

Line 476 adds a comma before and

Line 477 adds the before nucleus

Line 477 changes resulting to results

Line 478 changes in duces to induces

Line 478 adds space between TheNF-κB

Line 484 adds a comma before and

Line 489 adds a comma before and

Line 494 adds a comma before and

Line 495 changes cost to costs

Line 496 changes compounds to compound

Line 497 changes arthritics to arthritic

line 519 adds the before CIA and adds a comma after model

line 527 adds a comma before and   

line 531 changes Curcumin loaded to Curcumin-loaded

Line 549 remove the comma after activation

line 561 changes were resulted to have resulted in

line 563 changes treat to treating

line 564 adds a comma before and

line 567 changes formulation to formulations

line 567 changes demonstrated to demonstrating

Line 576 who discovered it???

Line 577 changes ration to ratio

Line 580 changes curcumin loaded to curcumin-loaded

Line 587 removes the after into

line 589 remove the before joint

line 590 adds a comma before and

line 593 adds a comma before and

line 598 changes patients to patient’s

line 599 changes effect to effects

line 603 changes effective strategy to to an effective strategy for

line 606 changes prevent to preventing

line 607 changes address to clinic application on to  address the clinical application of  

line 607 changes for treat to to treat

 

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Major points

1. The inflammasome section is not properly described. Firstly, the inflammasome classification, according to the current literature classifies inflammasome in canonical, non-canonical and alternative inflammasome. The author should discuss all three types of inflammasome in pathophysiology contexts and their molecular mechanisms.

2. The authors report that, “based on the nucleotide-binding oligomerization domain, the inflammasome can be classified into four groups (NODs, NLRPs, NLRC4 and NLRC5)”, however, NOD domains include NLRPs as well as NLRCs and do not constitute a different group. Moreover, Pyrin inflammasome is not mentioned at all – “pyrin is quite distinct among inflammasome-forming receptors and only shares the PYD domain with other inflammasomes” [Function and mechanism of the pyrin inflammasome, Rosalie Heilig and Petr Broz, 2017, European Journal of Immunology, https://doi.org/10.1002/eji.201746947], therefore is classified as an additional independent inflammasome.  In my opinion the author should discuss more deeply these aspects to give comprehensive description of the field of the inflammasome as well as their involvements in diseases.

3. At today the non-canonical inflammasome is better characterize than before, although not as good as the canonical inflammasome, however the authors mention the activation of caspase-11 as a marker for the non-canonical one. Caspase-11 is murine caspase not human; its human homologous are caspase-4 and -5 which are not mentioned at all.

4. The 2 steps that lead to the fully activation of the inflammasome, which are common to all the canonical inflammasomes are not described. For instance, the engagement of TLRs for the “priming step” is not described; LPS, which primes the most well characterized inflammasome (NLRP3) is not even mentioned in the inflammasome paragraph.

The molecular mechanism of activation of the speck formation is missed. All the inflammasomes form a single speck, however, NLRP3 speck is located at the perinuclear region and co-localize with MTOC, which makes this inflammasome different from others, where the single speck is within the cytosol w/o a specific structural cytosolic marker. Moreover, the fully activation of NLRP3 needs TGN, ox-mtDNA, NEK7 and cytoskeleton rupture which makes this inflammasome unique. All these aspects should be discussed more in detail.

The authors report that exists three models for NLRP3 inflammasome activation, however, all these activators bring to ROS production. The presence of ROS as intermediated is not a separated model but belong to all the mechanisms described today. Moreover, the bacterial toxin, nigericin, which represent one of the most potent stimuli, is missing. Here, several references are missing too.

The description of GSDMD should be put in the inflammasome section.

Finally, the role of the axis NLRP3-NETs-SARS-CoV2 should be also mentioned as a new potential target.

 

Minor points

In Fig.1 Active Caspase 1 is spelled wrongly; NLRC5 is not drawn

The single speck is 0.8-1 um not 1 uM

In Fig.2 the NLRP3 inflammasome has been drawn with NEK7 protein, which is needed for the fully activation, but it is not reported in the text; NLRP3, the 3 is missing in the inactive form

Author Response

Please see the attachment

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The authors have appropriately corrected the manuscript according to the comments

Reviewer 2 Report

I believe the manuscript has been sufficiently improved to warrant
publication in Molecules

Back to TopTop